Jianping Xiong
A5068044246- Cancer-related molecular mechanisms research
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Lung Cancer Treatments and Mutations
- RNA modifications and cancer
- Gastric Cancer Management and Outcomes
- Ferroptosis and cancer prognosis
- Cancer-related gene regulation
- MicroRNA in disease regulation
- Lung Cancer Research Studies
- Advanced Radiotherapy Techniques
- Hippo pathway signaling and YAP/TAZ
- Circular RNAs in diseases
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer-related Molecular Pathways
- Lung Cancer Diagnosis and Treatment
- Pancreatic and Hepatic Oncology Research
- Wnt/β-catenin signaling in development and cancer
- Cancer, Lipids, and Metabolism
- PARP inhibition in cancer therapy
- Ubiquitin and proteasome pathways
- Cancer Mechanisms and Therapy
- Cancer Treatment and Pharmacology
- Gastrointestinal Tumor Research and Treatment
First Affiliated Hospital of Nanchang University
2016-2025
Nanchang University
2016-2025
Nanjing Medical University
2013-2025
Jiangxi Provincial Cancer Hospital
2020-2025
First Affiliated Hospital of Jiangxi Medical College
2009-2025
First Affiliated Hospital of Shantou University Medical College
2025
Shanghai Innovative Research Center of Traditional Chinese Medicine
2025
Songjiang District Central Hospital
2025
Shantou University
2025
Chinese Academy of Medical Sciences & Peking Union Medical College
2019-2024
Purpose There is currently no standard treatment strategy for patients with advanced metastatic gastric cancer experiencing progression after two or more lines of chemotherapy. We assessed the efficacy and safety apatinib, a novel vascular endothelial growth factor receptor 2 tyrosine kinase inhibitor, in gastroesophageal junction adenocarcinoma whom at least prior chemotherapy had failed. Patients Methods This was randomized, double-blind, placebo-controlled phase III trial. from 32 centers...
Patients with metastatic gastric cancer (mGC) who do not respond to or experience progression second-line chemotherapy have no treatment options that clearly confer a survival benefit. This trial investigated the safety and efficacy of apatinib, an inhibitor vascular endothelial growth factor receptor, as option for heavily pretreated patients mGC.Patients experienced failure at least two chemotherapeutic regimens were randomly assigned receive placebo (group A), apatinib 850 mg once daily...
We assessed the efficacy and safety of camrelizumab [an anti-programmed death (PD-1) mAb] plus apatinib (a VEGFR-2 tyrosine kinase inhibitor) in patients with advanced hepatocellular carcinoma (HCC).This nonrandomized, open-label, multicenter, phase II study enrolled HCC who were treatment-naïve or refractory/intolerant to first-line targeted therapy. Patients received intravenous 200 mg (for bodyweight ≥50 kg) 3 mg/kg <50 every 2 weeks oral 250 daily. The primary endpoint was objective...
Cetuximab in combination with chemotherapy is a standard-of-care first-line treatment regimen for patients
Aumolertinib (formerly almonertinib; HS-10296) is a novel third-generation epidermal growth factor receptor tyrosine kinase inhibitor approved in China. This double-blind phase III trial evaluated the efficacy and safety of aumolertinib compared with gefitinib as first-line treatment for locally advanced or metastatic EGFR-mutated non-small-cell lung cancer (NSCLC; ClinicalTrials.gov identifier: NCT03849768).Patients at 53 sites China were randomly assigned 1:1 to receive either (110 mg)...
Abstract Intratumoral genomic heterogeneity in glioblastoma (GBM) is a barrier to overcoming therapy resistance. Treatments that are effective independent of genotype urgently needed. By correlating intracellular metabolite levels with radiation resistance across dozens genomically-distinct models GBM, we find purine metabolites, especially guanylates, strongly correlate Inhibiting GTP synthesis radiosensitizes GBM cells and patient-derived neurospheres by impairing DNA repair. Likewise,...
Abstract Background Association of immune-related adverse events with tumor response has been reported. Reactive cutaneous capillary endothelial proliferation (RCCEP) is the most common event related to camrelizumab, an immune checkpoint inhibitor, but lack comprehensive analyses. In this study, we conducted analyses on RCCEP in advanced hepatocellular carcinoma (HCC) patients treated camrelizumab monotherapy. Methods Data were derived from a Chinese nationwide, multicenter phase 2 trial...
Pancreatic cancer is characterized by aggressive and highly metastatic phenotypes. This disease exhibits a poor patient prognosis considered challenge due to the limited treatment options encountered in clinical practice. Previous studies have shown that ruscogenin, saponin found root of Ophiopogon japonicus, exerts wide range biological functions including anticancer activity. In present study, effects ruscogenin were investigated on pancreatic cells potential molecular mechanism this...
GEM20110714 (ClinicalTrials.gov identifier: NCT01528618), the first randomized, phase III study of systemic chemotherapy in recurrent or metastatic nasopharyngeal carcinoma (NPC), reported significant progression-free survival improvement with gemcitabine plus cisplatin (GP) versus fluorouracil (FP; hazard ratio, 0.55; 95% CI, 0.44 to 0.68;
Background This study aimed to evaluate the antitumor activity of camrelizumab, an antiprogrammed cell death-1 antibody, in pretreated recurrent or metastatic nasopharyngeal carcinoma (NPC) and explore predictive biomarkers. Methods Patients with (not amenable locally curative treatment) NPC who had failed at least two lines chemotherapy were eligible receive camrelizumab (200 mg intravenously every 2 weeks) for years until disease progression, intolerable adverse events, withdrawal...
Abstract Background The effectiveness of anti-programmed cell death protein 1(PD-1)/programmed 1 ligand 1(PD-L1) therapy in treating certain types cancer is associated with the level PD-L1. However, this relationship has not been observed colorectal (CRC), and underlying regulatory mechanism PD-L1 CRC remains unclear. Methods Binding TMEM160 to was determined by co-immunoprecipitation (Co-IP) GST pull-down assay.The ubiquitination levels were verified using assay. Phenotypic experiments...
191 Background: Glecirasib (JAB-21822), a highly selective, covalent and oral KRAS G12C inhibitor, has demonstrated favorable safety profile promising efficacy result as monotherapy in NSCLC. We previously reported preliminary data of glecirasib (NCT05009329) combination with cetuximab (NCT05194995) G12C-mutated advanced Colorectal Cancer (CRC); here, we present the updated results. Methods: Patients (pts) CRC harboring mutation were enrolled treated either single agent (800mg QD) or...
In addition to the high neurotoxicity, depression, and anxiety are most prominent characteristics of methamphetamine (Meth) withdrawal. Studies date on issue Meth-associated depression focused brain, however, whether peripheral homeostasis, especially "microbiota-gut" axis participates in these adverse outcomes, remains poorly understood. current study, with fecal microbiota transplantation (FMT) assay, mice received from Meth withdrawal displayed marked behaviors. The 16S rRNA sequencing...
Urokinase-type plasminogen activator receptors (uPARs), up-regulated during tumor progression, associate with β1 integrins, localizing urokinase to sites of cell attachment. Binding uPAR the β-propeller α3β1 empowers vitronectin adhesion by this integrin. How modifies other integrins remains unknown. Using recombinant proteins, we found directly binds α5β1 and rather than blocking, renders fibronectin (Fn) binding Arg-Gly-Asp (RGD) resistant. This resulted from RGD-independent α5β1–uPAR Fn...